Johnson & Johnson Halda Acquisition $3.05 Billion
Johnson & Johnson Halda acquisition bolsters J&J's oncology pipeline; HLD-0915 data and about $0.15 2026 adjusted EPS hit could drive near-term flows.
KEY TAKEAWAYS
- Johnson & Johnson agreed to acquire Halda for $3.05 billion in cash, subject to Hart-Scott-Rodino and closing conditions.
- HLD-0915 Phase 1/2 data showed 59% >50% PSA reduction and 32% >90% reduction among 22 evaluable patients.
- Deal will reduce 2026 adjusted EPS by about $0.15 due to short-term financing and related charges.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
On Nov. 17, 2025, Johnson & Johnson (JNJ) announced it will acquire Halda Therapeutics to strengthen its oncology portfolio, focusing on solid tumors and metastatic castration-resistant prostate cancer.
Acquisition Terms and Timing
Johnson & Johnson will buy Halda Therapeutics for the figure in cash, subject to customary closing adjustments. The transaction is expected to close within the next few months, pending regulatory approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Clinical Data and Pipeline
Halda’s lead asset, HLD-0915, is a first-in-class, oral Regulated Induced Proximity Targeting Chimera (RIPTAC) therapeutic in Phase 1/2 development for metastatic castration-resistant prostate cancer. Recent testing showed the candidate was well tolerated and demonstrated encouraging anti-tumor activity, including reductions in prostate-specific antigen (PSA) and RECIST tumor responses in heavily pretreated patients.
Among 22 evaluable patients, 59.0% achieved more than 50.0% PSA reduction and 32.0% achieved more than 90.0% reduction. All grade-3-or-higher treatment-related adverse events were reversible, with no treatment-related deaths. Dose expansion will focus on 25 mg and 50 mg regimens for registrational studies. Halda’s pipeline also includes additional RIPTAC-based candidates targeting other solid tumors.
Christian S. Schade, Halda’s president and CEO, said, “This announcement is a tribute to the years of scientific effort to develop this novel, first-in-class modality and deliver significant value to our shareholders.”
Financial Impact and Next Steps
Johnson & Johnson expects the acquisition to reduce its 2026 adjusted earnings per share by about $0.15 due to short-term financing and related charges. The company plans to accelerate ongoing studies of the lead candidate and integrate Halda’s platform to address resistance mechanisms in precision oncology. It also intends to leverage the platform for additional solid-tumor indications and potential applications beyond oncology.
